Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Equibles does not estimate personal net worth.
Get an email with a short summary when Akebia Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get AKBA alertsErik Ostrowski is recorded as CFO at Akebia Therapeutics, Inc. (AKBA) and CEO at Tectonic Therapeutic, Inc. (TECX) since May 1, 2023. The newest filing on record that lists Erik Ostrowski as CFO at Akebia Therapeutics, Inc. (AKBA) is dated April 28, 2026. Akebia Therapeutics, Inc. reported in an 8-K filed June 24, 2024 that Erik Ostrowski was appointed Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer and principal financial officer, effective June 24, 2024. Tectonic Therapeutic, Inc. reported in an 8-K filed June 20, 2024 that Erik Ostrowski resigned as President, Interim Chief Executive Officer and Chief Financial Officer (principal executive officer, principal financial officer, effective June 20, 2024. Tectonic Therapeutic, Inc. reported in an 8-K filed May 1, 2023 that Erik Ostrowski was appointed President and Interim Chief Executive Officer, effective May 1, 2023. The proxy statement of Akebia Therapeutics, Inc. reports total compensation of $1,792,361 for Erik Ostrowski in fiscal 2025, including a base salary of $552,919. Disclosed compensation is on record for 7 fiscal years. Erik Ostrowski has spoken on 5 earnings calls across 1 company, most recently for Akebia Therapeutics, Inc. on November 5, 2026. Akebia Therapeutics, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Tectonic Therapeutic, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Akebia Therapeutics, Inc. includes John Butler (CEO, CFO and Board Member), John P. Butler (CEO and Board Member), Ellen Snow (CFO) and 7 others.
“On June 24, 2024, Akebia Therapeutics, Inc. (the "Company") announced the appointment of Erik Ostrowski as the Company's Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer and principal financial officer, effective June 24, 2024 (the "Effective Date").”
“Immediately prior to the Merger, Erik Ostrowski, Steven Avruch, Azadeh Golipour, Ph.D. and Essra Ridha, M.D., MRCP, FFPM resigned from all of their offices with AVROBIO and all of its subsidiaries, if applicable, including, with respect to Mr. Ostrowski, as AVROBIO's President, Interim Chief Executive Officer and Chief Financial Officer (principal executive officer, principal financial officer and principal accounting officer).”
“Total revenues decreased to $36.9 million in Q326 from $58.8 million in Q325.”
“Total revenues were $49.1 million in Q2 26 compared to $62.5 million in Q2 25. This decrease was due to lower Eryxia revenues, which were partially offset by higher VAPTIO.”
“We're pleased to deliver a Vastio revenue growth this quarter as we continue our pursuit to make Vastio a standard of care for the treatment of anemia and dialysis patients with CKD.”
“As John mentioned, we saw a strong top-line performance in calendar year 25, as net product revenues increased nearly 50% over calendar year 24, driven by the U.S. introduction of Vasio and increased sales of Rixia.”
2023-05-01–present
Start not stated–present
Last confirmed April 28, 2026
Source not stated
Start not stated–2021-04-22
Last confirmed by a filing; no departure on record
Start not stated–2024-06-20
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Akebia Therapeutics, Inc. (AKBA) | Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer | $552,919 | $1,792,361 |
| 2024 | Akebia Therapeutics, Inc. (AKBA) | Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer | $284,414 | $1,215,122 |
| 2024 | Tectonic Therapeutic, Inc. (TECX) | M.B.A. Former President, Interim Chief Executive Officer, Chief Financial Officer and Treasurer | $254,125 | $1,093,258 |
| 2023 | Tectonic Therapeutic, Inc. (TECX) | M.B.A. Former President, Interim Chief Executive Officer, Chief Financial Officer and Treasurer | $504,400 | $1,590,892 |
| 2022 | Tectonic Therapeutic, Inc. (TECX) | President, Interim Chief Executive Officer, Chief Financial Officer and Treasurer | $460,000 | $1,352,093 |
| 2021 | Tectonic Therapeutic, Inc. (TECX) | President, Interim Chief Executive Officer, Chief Financial Officer and Treasurer | $439,254 | $2,705,607 |
| 2020 | Tectonic Therapeutic, Inc. (TECX) | Chief Financial Officer and Treasurer | $424,400 | $2,010,017 |
| 2019 | Tectonic Therapeutic, Inc. (TECX) | Chief Financial Officer and Treasurer | $412,000 | $2,753,795 |